{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/hypertension-not-diabetic/management/management/","result":{"pageContext":{"chapter":{"id":"d6332f04-a86e-56ef-9e25-d77083a8371c","slug":"management","fullItemName":"Scenario: Management","depth":2,"htmlHeader":"<!-- begin field 0e9ca348-bd7f-426e-a38c-f6b1d96c05f7 --><h2>Scenario: Management</h2><!-- end field 0e9ca348-bd7f-426e-a38c-f6b1d96c05f7 -->","summary":"Covers the management of hypertension.","htmlStringContent":"<!-- begin item 9739a0b4-3cb7-4166-abdb-5d05e3f42256 --><!-- begin field 30493e53-efae-49da-a7b6-acbd008717cc --><p>From age 18 years onwards.</p><!-- end field 30493e53-efae-49da-a7b6-acbd008717cc --><!-- end item 9739a0b4-3cb7-4166-abdb-5d05e3f42256 -->","topic":{"id":"c1c1e500-a3f1-5baa-8d5f-890b15f767cc","topicId":"8de59d12-a526-4ab9-8496-1fcb59d838ff","topicName":"Hypertension - not diabetic","slug":"hypertension-not-diabetic","lastRevised":"Last revised in September 2020","chapters":[{"id":"2f82c42a-b82b-549e-9b10-218d9f782bf8","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"a5985652-a8b7-51c0-b2d2-6836d4507f90","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"95f1a40b-c079-5c37-af45-5e0806a2bcae","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"4f16b189-bff9-5dfe-82a9-fdd4cd035ab0","slug":"changes","fullItemName":"Changes"},{"id":"a4dad1ea-40da-5ed2-85b0-8b5ea72bc196","slug":"update","fullItemName":"Update"}]},{"id":"b0107535-58ec-5e22-ac3b-22ae41ade390","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"f76e08e3-badc-526a-835f-8f549cc3f784","slug":"goals","fullItemName":"Goals"},{"id":"928c1147-d56a-5b8a-94f7-87ddad3ef460","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"aae28613-e6a5-5ba1-b4fa-e5032a9918ac","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"7bf8c570-8757-5ae3-802f-5cba9e5ceb86","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"3ace22a3-d042-5a6a-9d63-3527cf484a0a","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"c1a38cc6-4765-5c16-9f08-592cfc9851a3","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"066993d8-fd33-59fb-877b-6e8418b515d1","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"15ade196-5491-5552-9df6-a17d4c9c69d7","slug":"definition","fullItemName":"Definition"},{"id":"4528059a-b33b-51d3-8c65-983b4c165a3a","slug":"prevalence","fullItemName":"Prevalence"},{"id":"3e698434-11c9-553c-96a6-a249bf121cbb","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"0bec257d-f02e-5030-a430-8accc5245e7f","slug":"complications-prognosis","fullItemName":"Complications and prognosis"}]},{"id":"e56e7d7e-9afc-5c38-a77a-8f2b80461457","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"7dcedb3e-c4f4-55ff-9910-03ee5ed41bb4","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"a6466983-7adb-5a4f-8864-f3ecc06b447a","slug":"investigations","fullItemName":"Investigations"}]},{"id":"33227758-4699-5e51-be33-b22dca2eb654","fullItemName":"Management","slug":"management","subChapters":[{"id":"d6332f04-a86e-56ef-9e25-d77083a8371c","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"0cfca07e-cadc-55c1-81ed-fcdb236f4835","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"92190a49-9e8d-5fae-93b2-cf6243cfc01b","slug":"angiotensin-converting-enzyme-inhibitors","fullItemName":"Angiotensin-converting enzyme inhibitors"},{"id":"5ee249d0-bc66-59a5-8138-2449798ff2eb","slug":"angiotensin-ii-receptor-blockers","fullItemName":"Angiotensin-II receptor blockers"},{"id":"115bec24-ba4e-5f2a-80dc-dee6e948a288","slug":"thiazide-type-diuretics","fullItemName":"Thiazide-type diuretics"},{"id":"2ae4ccdd-d119-5a5a-9c89-d6493f2552f2","slug":"calcium-channel-blockers","fullItemName":"Calcium-channel blockers"},{"id":"44681f3b-7958-5edd-a944-eb440f1df250","slug":"spironolactone","fullItemName":"Spironolactone"},{"id":"cb9a67f7-3588-5c68-b3d5-6c63d50ad0b8","slug":"beta-blockers","fullItemName":"Beta-blockers"},{"id":"5740c79c-d5a7-5547-ab38-db87df2b9121","slug":"alpha-blockers","fullItemName":"Alpha-blockers"},{"id":"f3424e7c-5446-59b0-b50e-0724587bb306","slug":"covid-19","fullItemName":"COVID-19"}]},{"id":"3b3191c9-bff5-563f-b5c0-09e8a0d22441","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"7d204db0-8ff2-556e-97b4-89516ac7819b","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"0f686cda-dcaf-5f12-b5d6-871aefae47fe","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"dfcaec55-3c23-5a3f-9c08-f151a3120dc2","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"804073cd-b49f-5e4a-bf85-90faf125ad0e","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"613e4289-93db-5311-aa87-b5a7a6e82dd1","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"6e42a873-c39f-5405-bf4f-efdd81187ea2","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"2b87bc1c-2b4a-556b-b320-6b4f18bcf85d","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"33227758-4699-5e51-be33-b22dca2eb654","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"3e0a368a-a86e-52aa-9909-6cc110b06248","slug":"managing-hypertension","fullItemName":"Managing hypertension","depth":3,"htmlHeader":"<!-- begin field cd4f3211-a6b7-49d3-83a5-4ca2122f1e8f --><h3>How should I manage a person with hypertension?</h3><!-- end field cd4f3211-a6b7-49d3-83a5-4ca2122f1e8f -->","summary":null,"htmlStringContent":"<!-- begin item 30657a4f-1f6a-4a54-a404-8249e3d6dff4 --><!-- begin field ac402778-f541-4141-a674-1808146729ac --><p><strong>These recommendations do not apply to people with diabetes or chronic kidney disease (CKD) or to women who are considering pregnancy, pregnant, or breastfeeding. For information on managing hypertension in people with diabetes or CKD, see the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/diabetes-type-1/\">Diabetes - type 1</a>, <a class=\"topic-reference external-reference\" href=\"/topics/diabetes-type-2/\">Diabetes - type 2</a>, and <a class=\"topic-reference external-reference\" href=\"/topics/chronic-kidney-disease/\">Chronic kidney disease</a>. For information on managing hypertension in women who are considering pregnancy, pregnant, or breastfeeding, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/hypertension-in-pregnancy/\">Hypertension in pregnancy</a>.</strong></p><ul><li><strong>Refer for same-day specialist assessment if the person has: </strong><ul><li>A clinic blood pressure of 180/120 mmHg and higher with:<ul><li>Signs of retinal haemorrhage and/or papilloedema (<a class=\"topic-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/background-information/definition/\">accelerated hypertension</a>) <em>or</em></li><li>Life-threatening symptoms, such as new onset confusion, chest pain, signs of heart failure, or acute kidney injury. </li></ul></li><li>Suspected phaeochromocytoma, for example labile or postural hypotension, headache, palpitations, pallor, abdominal pain, or diaphoresis. </li></ul></li><li><strong>If referral is not indicated: </strong><ul><li><strong>Carry out investigations for target organ damage, followed by a formal assessment of the person's cardiovascular risk,</strong> if not already done. For more information, see the section on <a class=\"topic-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/diagnosis/investigations/\">Investigations</a>.</li><li><strong>Offer lifestyle advice, and continue to offer it periodically. </strong><ul><li><strong>Diet and exercise</strong> — explain that a healthy diet and regular exercise can reduce blood pressure. If the person is overweight or obese, offer weight loss advice. For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/obesity/\">Obesity</a>. </li><li><strong>Caffeine</strong> — discourage excessive consumption of coffee and other caffeine-rich products.</li><li><strong>Dietary sodium</strong> — encourage people to keep their dietary sodium intake low, by reducing or substituting sodium salt, as this can reduce blood pressure. Be aware that salt substitutes containing potassium chloride should not be used by older people, people with diabetes, pregnant women, people with kidney disease, and people taking some antihypertensive drugs (such as angiotensin converting enzyme inhibitors and angiotensin-II receptor blockers). Encourage salt reduction in these groups of people.</li><li><strong>Smoking</strong> — offer advice and help to smokers to stop smoking. For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/smoking-cessation/\">Smoking cessation</a>.</li><li><strong>Alcohol </strong>— if the person drinks excessively, encourage a reduced intake because this can reduce blood pressure and has broader health benefits. For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/alcohol-problem-drinking/\">Alcohol - problem drinking</a>.</li></ul></li><li><strong>Offer patient information leaflets on hypertension, </strong>for example <a data-hyperlink-id=\"a877e4ef-f0fd-4621-860b-a8f70151ff92\" href=\"https://www.bhf.org.uk/publications/heart-conditions/blood-pressure\">Blood pressure</a> from the British Heart Foundation (BHF) and <a data-hyperlink-id=\"05804920-ec0f-45b5-9d42-a8f701520109\" href=\"https://www.bda.uk.com/foodfacts/hypertension.pdf\">Hypertension and diet</a> from the British Dietetic Association (BDA).</li><li><strong>For stage 2 hypertension </strong>(clinic blood pressure of 160/100 mmHg or higher but less than 180/120 mmHg <em>and</em> subsequent ambulatory daytime average or home blood pressure average of 150/95 mmHg or higher):<ul><li>Offer <a class=\"topic-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/management/management/#antihypertensive-drug-treatment\">antihypertensive drug treatment</a> in addition to lifestyle advice to adults with persistent stage 2 hypertension, regardless of age.</li><li>Use clinical judgement for people with frailty or multimorbidity. For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/multimorbidity/\">Multimorbidity</a>.</li></ul></li><li><strong>For stage 1 hypertension </strong>(clinic blood pressure ranging from 140/90 mmHg to 159/99 mmHg <em>and</em> subsequent ambulatory daytime average or home blood pressure average ranging from 135/85 mmHg to 149/94 mmHg):<ul><li>Discuss starting <a class=\"topic-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/management/management/#antihypertensive-drug-treatment\">antihypertensive drug treatment</a>, in addition to lifestyle advice, with people aged under 80 years with persistent stage 1 hypertension who have 1 or more of the following: target organ damage, established cardiovascular disease (CVD), renal disease, diabetes, an estimated 10-year risk of CVD of 10% or more. </li><li>Consider <a class=\"topic-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/management/management/#antihypertensive-drug-treatment\">antihypertensive drug treatment</a> in addition to lifestyle advice for people aged under 60 years with stage 1 hypertension and an estimated 10-year CVD risk below 10%. Bear in mind that 10-year cardiovascular risk may underestimate the lifetime probability of developing CVD.</li><li>Consider<strong> </strong><a class=\"topic-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/management/management/#antihypertensive-drug-treatment\">antihypertensive drug treatment</a> in addition to lifestyle advice for people aged over 80 years with a clinic blood pressure of over 150/90 mmHg.</li><li>Use clinical judgement for people with frailty or multimorbidity. For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/multimorbidity/\">Multimorbidity</a>.</li></ul></li><li><strong>Discuss with the person</strong> their individual CVD risk and their preferences for treatment, including no treatment, and explain the risks and benefits before starting antihypertensive drug treatment. Continue to offer lifestyle advice, and support them to make lifestyle changes whether or not they choose to start antihypertensive drug treatment.</li><li> <strong>For adults aged under 40 years with hypertension, </strong>consider seeking specialist evaluation of <a class=\"topic-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/diagnosis/investigations/#secondary-causes-of-hypertension\">secondary causes of hypertension</a> and a more detailed assessment of the long-term balance of treatment benefit and risks.</li><li><strong><a class=\"topic-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/management/management/#monitoring-treatment-targets\">Monitor</a> response to lifestyle changes or drug treatment. </strong></li></ul></li></ul><p><strong>The National Institute for Health and Care Excellence (NICE) has produced:</strong></p><ul><li>A <a data-hyperlink-id=\"e125ff0d-d584-4624-afbd-aaf1008465ef\" href=\"https://www.nice.org.uk/guidance/ng136/resources/visual-summary-pdf-6899919517\">2-page visual summary on the recommendations for diagnosing and treating hypertension</a>.</li><li>A <a data-hyperlink-id=\"022b7ab3-8b6e-4949-8598-aaf001748e58\" href=\"https://www.nice.org.uk/guidance/NG136/resources\">patient decision aid</a> on treatment options for hypertension to help people and their healthcare professionals discuss the different types of treatment and make a decision that is right for each person.</li></ul><!-- end field ac402778-f541-4141-a674-1808146729ac --><!-- end item 30657a4f-1f6a-4a54-a404-8249e3d6dff4 -->","subChapters":[{"id":"66f5b424-d036-5c9d-934c-744ba7e7e650","slug":"basis-for-recommendation-8d3","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field dec3a551-54de-40b1-9df1-2921c228862e --><h4>Basis for recommendation</h4><!-- end field dec3a551-54de-40b1-9df1-2921c228862e -->","summary":null,"htmlStringContent":"<!-- begin item 8d33cb65-17ec-490d-af45-5525792ad97b --><!-- begin field 4ee0e4c1-a695-4787-b493-dea16b9d558b --><p>These recommendations are based on the National Institute for Health and Care Excellence (NICE) guideline <em>Hypertension in adults: diagnosis and management </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/references/\">NICE, 2019</a>]. For information on why NICE made these recommendations and how they might affect practice, see the section on <a href=\"https://www.nice.org.uk/guidance/ng136/resources/hypertension-in-adults-diagnosis-and-management-pdf-66141722710213\" data-hyperlink-id=\"25937438-2d7a-4a16-807c-aaf1006a82e7\">Rationale and impact</a> in the NICE guideline <em>Hypertension in adults: diagnosis and management </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/references/\">NICE, 2019</a>].</p><!-- end field 4ee0e4c1-a695-4787-b493-dea16b9d558b --><!-- end item 8d33cb65-17ec-490d-af45-5525792ad97b -->","subChapters":[]}]},{"id":"57fea56e-968b-5069-b05d-2d3480cdce8e","slug":"antihypertensive-drug-treatment","fullItemName":"Antihypertensive drug treatment","depth":3,"htmlHeader":"<!-- begin field 62af68f5-481e-4b4c-bdcc-aaef0146470c --><h3>How should I prescribe antihypertensive drug treatment?</h3><!-- end field 62af68f5-481e-4b4c-bdcc-aaef0146470c -->","summary":null,"htmlStringContent":"<!-- begin item bcc9e139-978a-4661-9361-aaef014646ef --><!-- begin field 2f017dbe-476c-4198-844f-aaef0146470c --><p><strong>These recommendations do not apply to people with diabetes or chronic kidney disease (CKD) or to women who are considering pregnancy, pregnant, or breastfeeding. For information on managing hypertension in people with diabetes or CKD, see the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/diabetes-type-1/\">Diabetes - type 1</a>, <a class=\"topic-reference external-reference\" href=\"/topics/diabetes-type-2/\">Diabetes - type 2</a>, and <a class=\"topic-reference external-reference\" href=\"/topics/chronic-kidney-disease/\">Chronic kidney disease</a>. For information on managing hypertension in women who are considering pregnancy, pregnant, or breastfeeding, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/hypertension-in-pregnancy/\">Hypertension in pregnancy</a>.</strong></p><ul><li><strong>A single antihypertensive drug is often inadequate in the management of hypertension, and additional antihypertensive drugs are usually added in a stepwise manner until control is achieved. </strong><ul><li>Allow an interval of at least 4 weeks to determine response to treatment. Be aware that response to drug treatment may be affected by age and ethnicity.</li><li>Offer people with isolated systolic hypertension (systolic blood pressure 160 mmHg or more) the same treatment as people with both raised systolic and diastolic blood pressure. </li></ul></li><li><strong>Step 1 treatment </strong><ul><li>For people aged under 55 years who are <em>not</em> of black African or African–Caribbean family origin, offer an angiotensin-converting enzyme (ACE) inhibitor or an angiotensin-II receptor blocker (ARB), also known as an angiotensin-II receptor antagonist (AIIRA).<ul><li>If an ACE inhibitor is not tolerated, for example, because of cough, offer an ARB. </li><li>Do not combine an ACE inhibitor with an ARB to treat hypertension. </li></ul></li><li>For people aged 55 years or over and people of black African or African–Caribbean family origin (of any age), offer a calcium-channel blocker (CCB).<ul><li>If a CCB is not tolerated, for example, because of oedema, offer a thiazide-like diuretic, such as indapamide.</li></ul></li><li>If there is evidence of heart failure, offer a thiazide-like diuretic, such as indapamide. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/heart-failure-chronic/\">Heart failure - chronic</a> for more information.</li><li>If starting or changing diuretic treatment for hypertension, offer a thiazide-like diuretic, such as indapamide, in preference to a conventional thiazide diuretic, such as bendroflumethiazide or hydrochlorothiazide.<ul><li>For people already having treatment with bendroflumethiazide or hydrochlorothiazide who have stable, well-controlled blood pressure, continue with their current treatment.</li></ul></li><li>For detailed information on prescribing an ACE inhibitor, ARB, CCB, or thiazide-like diuretic, see the section on <a class=\"topic-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/prescribing-information/\">Prescribing information</a>.</li></ul></li><li><strong>Step 2 treatment </strong><ul><li>Before considering next step treatment for hypertension:<ul><li>Discuss with the person if they are taking their medicine as prescribed.</li><li>Support adherence to treatment, in line with the National Institute for Health and Care Excellence (NICE) guideline on <a data-hyperlink-id=\"d7c74aea-e1c0-49ee-8b9f-aafa01607b1c\" href=\"https://www.nice.org.uk/guidance/cg76\">Medicines adherence</a>.</li></ul></li><li>If hypertension is not controlled with step 1 treatment of an ACE inhibitor or ARB, offer the choice of one of the following drugs in addition to step 1 treatment:<ul><li>A CCB <em>or</em></li><li>A thiazide-like diuretic.</li></ul></li><li>If hypertension is not controlled with step 1 treatment of a CCB, offer the choice of one of the following drugs in addition to step 1 treatment:<ul><li>An ACE inhibitor or ARB (consider an ARB in preference to an ACE inhibitor in people of black African or African–Caribbean family origin) <em>or</em></li><li>A thiazide-like diuretic.</li></ul></li><li>For detailed information on prescribing an ACE inhibitor, ARB, CCB, or thiazide-like diuretic, see the section on <a class=\"topic-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/prescribing-information/\">Prescribing information</a>.</li></ul></li><li><strong>Step 3 treatment</strong><ul><li>Before considering next step treatment for hypertension:<ul><li>Review the person's medications to ensure they are being taken at the optimal tolerated doses.</li><li>Discuss adherence to treatment, in line with the NICE guideline on <a data-hyperlink-id=\"879636d8-7f6c-4af2-9ee7-aafa01607b3d\" href=\"https://www.nice.org.uk/guidance/cg76\">Medicines adherence</a>.</li></ul></li><li>If hypertension is not controlled with step 2 treatment, offer a combination of:<ul><li>An ACE inhibitor or ARB (consider an ARB in preference to an ACE inhibitor in people of black African or African–Caribbean family origin), <em>and</em></li><li>A CCB, <em>and</em></li><li>A thiazide-like diuretic.</li></ul></li><li>For detailed information on prescribing an ACE inhibitor, ARB, CCB, or thiazide-like diuretic, see the section on <a class=\"topic-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/prescribing-information/\">Prescribing information</a>.</li></ul></li><li><strong>Step 4 treatment</strong><ul><li>If hypertension is not controlled in people taking the optimal tolerated doses of an ACE inhibitor or an ARB plus a CCB and a thiazide-like diuretic, regard them as having resistant hypertension. </li><li>Before considering further treatment for a person with resistant hypertension:<ul><li>Confirm elevated clinic blood pressure measurements using ambulatory or home blood pressure recordings.</li><li>Assess for postural hypotension.</li><li>Discuss adherence to treatment, in line with the NICE guideline on <a data-hyperlink-id=\"a7432236-0aea-4d1b-abfb-aafa01607b50\" href=\"https://www.nice.org.uk/guidance/cg76\">Medicines adherence</a>.</li></ul></li><li>For people with confirmed resistant hypertension, seek specialist advice or add a fourth antihypertensive drug.<ul><li>For people with a blood potassium level of 4.5 mmol/l or less, consider further diuretic therapy with low-dose spironolactone. Use particular caution in people with a reduced estimated glomerular filtration rate because they have an increased risk of hyperkalaemia. Monitor blood sodium and potassium, and renal function within 1 month of starting further diuretic therapy, and repeat as needed thereafter. </li><li>For people with blood potassium level of more than 4.5 mmol/l, consider an alpha-blocker or beta-blocker.</li></ul></li><li>If blood pressure remains uncontrolled in people with resistant hypertension taking the optimal tolerated doses of 4 drugs, seek specialist advice. </li><li>For detailed information on prescribing spironolactone, an alpha-blocker, or a beta-blocker, see the section on <a class=\"topic-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/prescribing-information/\">Prescribing information</a>.</li></ul></li></ul><p><strong> NICE has produced:</strong></p><ul><li>A <a data-hyperlink-id=\"022b7ab3-8b6e-4949-8598-aaf001748e58\" href=\"https://www.nice.org.uk/guidance/NG136/resources\">patient decision aid</a> on treatment options for hypertension to help people and their healthcare professionals discuss the different types of treatment and make a decision that is right for each person.</li><li>A <a data-hyperlink-id=\"e125ff0d-d584-4624-afbd-aaf1008465ef\" href=\"https://www.nice.org.uk/guidance/ng136/resources/visual-summary-pdf-6899919517\">2-page visual summary on the recommendations for diagnosing and treating hypertension</a>.</li></ul><!-- end field 2f017dbe-476c-4198-844f-aaef0146470c --><!-- end item bcc9e139-978a-4661-9361-aaef014646ef -->","subChapters":[{"id":"6c16e725-80f2-5163-9c93-f904a50a7f2e","slug":"basis-for-recommendation-27e","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 557032a4-e486-46c1-a355-aaef0146470e --><h4>Basis for recommendation</h4><!-- end field 557032a4-e486-46c1-a355-aaef0146470e -->","summary":null,"htmlStringContent":"<!-- begin item 27e8fbfb-b1e1-44f4-934f-aaef0146470e --><!-- begin field 15f2c736-c79f-4d22-8f97-aaef0146470e --><p>These recommendations are largely based on the National Institute for Health and Care Excellence (NICE) guideline <em>Hypertension in adults: diagnosis and management </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/references/\">NICE, 2019</a>]. For information on why NICE made these recommendations and how they might affect practice, see the section on <a href=\"https://www.nice.org.uk/guidance/ng136/resources/hypertension-in-adults-diagnosis-and-management-pdf-66141722710213\" data-hyperlink-id=\"25937438-2d7a-4a16-807c-aaf1006a82e7\">Rationale and impact</a> in the NICE guideline <em>Hypertension in adults: diagnosis and management </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/references/\">NICE, 2019</a>].</p><ul><li>The information that a single antihypertensive drug is often inadequate in the management of hypertension, and the recommendation to allow an interval of at least four weeks to determine response to treatment is based on the British National Formulary (BNF) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/references/\">Joint Formulary Committee, 2019</a>]. </li></ul><!-- end field 15f2c736-c79f-4d22-8f97-aaef0146470e --><!-- end item 27e8fbfb-b1e1-44f4-934f-aaef0146470e -->","subChapters":[]}]},{"id":"245242db-2531-5ee9-bd4d-f45c09851061","slug":"monitoring-treatment-targets","fullItemName":"Monitoring and treatment targets","depth":3,"htmlHeader":"<!-- begin field 805966d3-8133-4490-a30f-aaef012be6d4 --><h3>How should I monitor response to lifestyle changes or drug treatment in people with hypertension, and what are the treatment targets?</h3><!-- end field 805966d3-8133-4490-a30f-aaef012be6d4 -->","summary":null,"htmlStringContent":"<!-- begin item ee09545e-acd5-472e-8ca4-aaef012be69e --><!-- begin field 210e8901-065a-43e6-9521-aaef012be6d4 --><p><strong>These recommendations do not apply to people with diabetes or chronic kidney disease (CKD) or to women who are considering pregnancy, pregnant, or breastfeeding. For information on managing hypertension in people with diabetes or CKD, see the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/diabetes-type-1/\">Diabetes - type 1</a>, <a class=\"topic-reference external-reference\" href=\"/topics/diabetes-type-2/\">Diabetes - type 2</a>, and <a class=\"topic-reference external-reference\" href=\"/topics/chronic-kidney-disease/\">Chronic kidney disease</a>. For information on managing hypertension in women who are considering pregnancy, pregnant, or breastfeeding, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/hypertension-in-pregnancy/\">Hypertension in pregnancy</a>.</strong></p><ul><li><strong>Use clinic blood pressure measurements to monitor the response to lifestyle changes or drug treatment in people with hypertension.</strong><ul><li><strong>Aim to reduce and maintain blood pressure at the following levels:</strong><ul><li>Adults aged under 80 years — clinic blood pressure below 140/90 mmHg.</li><li>Adults aged 80 years and over — clinic blood pressure below 150/90 mmHg. </li><li>People with frailty or multimorbidity — use clinical judgement. For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/multimorbidity/\">Multimorbidity</a>.</li></ul></li><li><strong>For people with symptoms of postural hypotension and people aged 80 years and over, </strong>measure standing as well as seated blood pressure.<ul><li>In people with a significant postural drop or symptoms of postural hypotension, treat to a blood pressure target based on standing blood pressure. </li><li>If the systolic blood pressure falls by 20 mmHg or more when the person is standing, review their treatment. Consider referral to specialist care if symptoms of postural hypotension persist.</li></ul></li></ul></li><li><strong>For people with hypertension identified as having a <a class=\"topic-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/background-information/definition/\">&#39;white-coat&#39; effect</a> or <a class=\"topic-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/background-information/definition/\">masked hypertension</a>, </strong>consider <a class=\"topic-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/diagnosis/diagnosis/\">ambulatory blood pressure monitoring</a> (ABPM) or <a class=\"topic-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/diagnosis/diagnosis/\">home blood pressure monitoring</a> (HBPM), in addition to clinic blood pressure measurements.<ul><li>For people who use HBPM, ensure that they are trained on how to use the home blood pressure monitors. Provide information on what they should do if they are not achieving their target blood pressure. </li><li>When using ABPM or HBPM to monitor the response to treatment in adults with hypertension, use the average blood pressure level taken during the person's usual waking hours. For more information, see the section on <a class=\"topic-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/diagnosis/\">Diagnosis</a>.</li><li><strong>Aim to reduce and maintain blood pressure at the following levels:</strong><ul><li>Adults aged under 80 years — ABPM/HBPM below 135/85 mmHg.</li><li>Adults aged 80 years and over — ABPM/HBPM below 145/85 mmHg.</li><li>People with frailty or multimorbidity — use clinical judgement. For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/multimorbidity/\">Multimorbidity</a>.</li></ul></li><li>Be aware that the corresponding measurements for ABPM and HBPM are 5 mmHg lower than for clinic measurements. For more information on diagnostic thresholds, see the section on <a class=\"topic-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/diagnosis/\">Diagnosis</a>.</li></ul></li><li><strong>For people with hypertension who choose to self-monitor their blood pressure, </strong>advise them to use <a class=\"topic-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/diagnosis/diagnosis/\">HBPM</a>.<ul><li>Ensure that they are trained on how to use the home blood pressure monitors. Provide information on what they should do if they are not achieving their target blood pressure. </li><li>When using HBPM to monitor the response to treatment in adults with hypertension, use the average blood pressure level taken during the person's usual waking hours. For more information, see the section on <a class=\"topic-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/diagnosis/\">Diagnosis</a>.</li><li><strong>Aim to reduce and maintain blood pressure at the following levels:</strong><ul><li>Adults aged under 80 years — HBPM below 135/85 mmHg.</li><li>Adults aged 80 years and over — HBPM below 145/85 mmHg.</li><li>People with frailty or multimorbidity — use clinical judgement. For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/multimorbidity/\">Multimorbidity</a>.</li></ul></li><li>Be aware that the corresponding measurements for HBPM are 5 mmHg lower than for clinic measurements. For more information on diagnostic thresholds, see the section on <a class=\"topic-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/diagnosis/\">Diagnosis</a>.</li></ul></li><li><strong>Provide an <a class=\"topic-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/management/management/#annual-review-of-care\">annual review of care</a> to discuss the person's lifestyle, symptoms, and treatment(s), monitor the person's blood pressure and provide support.</strong></li></ul><!-- end field 210e8901-065a-43e6-9521-aaef012be6d4 --><!-- end item ee09545e-acd5-472e-8ca4-aaef012be69e -->","subChapters":[{"id":"ef3a2022-c14f-5545-9311-fceb935f3b92","slug":"basis-for-recommendation-84a","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field e29a6ed8-e3d5-47ca-b3a0-aaef012be6da --><h4>Basis for recommendation</h4><!-- end field e29a6ed8-e3d5-47ca-b3a0-aaef012be6da -->","summary":null,"htmlStringContent":"<!-- begin item 84a7a7b8-2c87-4c11-89b6-aaef012be6d9 --><!-- begin field db0afc01-2653-40a0-93ac-aaef012be6da --><p>These recommendations are largely based on the National Institute for Health and Care Excellence (NICE) guideline <em>Hypertension in adults: diagnosis and management </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/references/\">NICE, 2019</a>]. For information on why NICE made these recommendations and how they might affect practice, see the section on <a href=\"https://www.nice.org.uk/guidance/ng136/resources/hypertension-in-adults-diagnosis-and-management-pdf-66141722710213\" data-hyperlink-id=\"25937438-2d7a-4a16-807c-aaf1006a82e7\">Rationale and impact</a> in the NICE guideline <em>Hypertension in adults: diagnosis and management </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/references/\">NICE, 2019</a>].</p><!-- end field db0afc01-2653-40a0-93ac-aaef012be6da --><!-- end item 84a7a7b8-2c87-4c11-89b6-aaef012be6d9 -->","subChapters":[]}]},{"id":"c206c41f-94cb-56e9-abef-6773b892610d","slug":"annual-review-of-care","fullItemName":"Annual review of care","depth":3,"htmlHeader":"<!-- begin field c10f96c5-757b-4821-9da1-ab0801069b95 --><h3>How should I review the person annually?</h3><!-- end field c10f96c5-757b-4821-9da1-ab0801069b95 -->","summary":null,"htmlStringContent":"<!-- begin item 16361ecb-548a-4e05-94f7-ab0801069b16 --><!-- begin field 5ca1f01c-9fc2-46f6-9b26-ab0801069b95 --><p><strong>These recommendations <em>do not</em> apply to people with diabetes or chronic kidney disease (CKD) or to women who are considering pregnancy, pregnant, or breastfeeding. For information on managing hypertension in people with diabetes or CKD, see the CKS topics on </strong><a class=\"topic-reference external-reference\" href=\"/topics/diabetes-type-1/\">Diabetes - type 1</a><strong>, </strong><a class=\"topic-reference external-reference\" href=\"/topics/diabetes-type-2/\">Diabetes - type 2</a><strong>, and </strong><a class=\"topic-reference external-reference\" href=\"/topics/chronic-kidney-disease/\">Chronic kidney disease</a><strong>. For information on managing hypertension in women who are considering pregnancy, pregnant, or breastfeeding, see the CKS topic on </strong><a class=\"topic-reference external-reference\" href=\"/topics/hypertension-in-pregnancy/\">Hypertension in pregnancy</a><strong>.</strong></p><p><strong>At the annual review:</strong></p><ul><li><strong>Encourage adherence to treatment. </strong><ul><li>If necessary, use interventions to overcome medication non-adherence, such as suggesting the recording of medicine-taking, encouraging monitoring of the condition, simplifying the dosing regimen, and/or using a multi-compartment medicines system.</li></ul></li><li><strong>Check blood pressure.</strong><ul><li>If the person's blood pressure is above the <a class=\"topic-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/management/management/#monitoring-treatment-targets\">target range</a>, confirm that it is persistently raised by:<ul><li>Rechecking blood pressure on 2–3 occasions over the next few weeks or months (depending on clinical judgement), <em>or</em></li><li>If a <a class=\"topic-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/background-information/definition/\">&#39;white-coat&#39; effect</a> is suspected, considering <a class=\"topic-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/diagnosis/diagnosis/\">ambulatory blood pressure monitoring</a> (ABPM) or <a class=\"topic-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/diagnosis/diagnosis/\">home blood pressure monitoring</a> (HBPM).  </li></ul></li><li>If blood pressure is persistently raised above the target range, ensure that <a class=\"topic-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/diagnosis/investigations/#secondary-causes-of-hypertension\">secondary causes for hypertension</a> have been excluded, and consider <a class=\"topic-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/management/management/#antihypertensive-drug-treatment\">additional antihypertensive drug treatment</a>.</li><li>If the person's blood pressure is within the target range but adverse effects of the current antihypertensive drug treatment(s) are unacceptable, consider an <a class=\"topic-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/management/management/#antihypertensive-drug-treatment\">alternative antihypertensive drug treatment</a>.</li><li>If the person's blood pressure is within the target range and the treatment is well tolerated, review the person in a further 12 months.<ul><li>Consider a trial of stopping or reducing antihypertensive drug treatment for people whose blood pressure has been well controlled for years and who have favourable factors, such as use of only one antihypertensive drug, younger age, lower blood pressure, hypertension identified as having a <a class=\"topic-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/background-information/definition/\">&#39;white-coat&#39; effect</a>, and the successful implementation of lifestyle measures (such as weight loss, reduced alcohol consumption, regular exercise, and restriction of salt consumption).</li><li>Withdraw antihypertensive drugs gradually, following the manufacturer's guidance, and follow up the person carefully (for example at 4-weekly intervals for 6 months, then 2 or 3 times a year) to detect any recurrence of hypertension.</li></ul></li></ul></li><li><strong>Check renal function by measuring serum creatinine, electrolytes, and estimated glomerular filtration rate (eGFR), and dipstick urine to check for proteinuria.</strong><ul><li>If proteinuria is present, consider checking the urine albumin:creatinine ratio (ACR), ideally tested on a first-void morning urine sample.</li><li>If the eGFR is less than 60 mL/min/1.73 m² and/or the urinary ACR is 3 mg/mmol or more, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/chronic-kidney-disease/\">Chronic kidney disease</a> for information on confirming and managing CKD.</li></ul></li><li><strong>For people who are not on an antiplatelet drug or a statin, reassess their cardiovascular disease risk using the <a data-hyperlink-id=\"4756249f-6213-491f-9a49-aa0200a2c67a\" href=\"https://qrisk.org/three/\">QRISK®</a> assessment tool.</strong><ul><li>For information on the management of people with a 10-year cardiovascular risk of 10% or more (including prescribing statins and anti-platelet therapy), see the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/cvd-risk-assessment-management/\">CVD risk assessment and management</a>, <a class=\"topic-reference external-reference\" href=\"/topics/lipid-modification-cvd-prevention/\">Lipid modification - CVD prevention</a>, and <a class=\"topic-reference external-reference\" href=\"/topics/antiplatelet-treatment/\">Antiplatelet treatment</a>. </li></ul></li><li><strong>Consider offering details of organizations where people with hypertension can share views and obtain information, </strong>such as the Blood Pressure Association (<a data-hyperlink-id=\"9d53cf12-feb9-4295-a87b-a8f701570ad0\" href=\"http://www.bpassoc.org.uk/\">www.bpassoc.org.uk</a>).</li></ul><!-- end field 5ca1f01c-9fc2-46f6-9b26-ab0801069b95 --><!-- end item 16361ecb-548a-4e05-94f7-ab0801069b16 -->","subChapters":[{"id":"e94ae27e-3958-5105-a6c2-6b6660f169d4","slug":"basis-for-recommendation-2d4","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 787e0abe-4317-433e-af44-ab0801069ba1 --><h4>Basis for recommendation</h4><!-- end field 787e0abe-4317-433e-af44-ab0801069ba1 -->","summary":null,"htmlStringContent":"<!-- begin item 2d49bba5-5e8d-4453-b833-ab0801069ba0 --><!-- begin field ea26d8c5-dffd-41d0-88a8-ab0801069ba1 --><p>These recommendations are largely based on the National Institute for Health and Care Excellence (NICE) guideline <em>Hypertension in adults: diagnosis and management </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/references/\">NICE, 2019</a>]. For information on why NICE made these recommendations and how they might affect practice, see the section on <a href=\"https://www.nice.org.uk/guidance/ng136/resources/hypertension-in-adults-diagnosis-and-management-pdf-66141722710213\" data-hyperlink-id=\"25937438-2d7a-4a16-807c-aaf1006a82e7\">Rationale and impact</a> in the NICE guideline <em>Hypertension in adults: diagnosis and management </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/references/\">NICE, 2019</a>].</p><!-- end field ea26d8c5-dffd-41d0-88a8-ab0801069ba1 --><!-- end item 2d49bba5-5e8d-4453-b833-ab0801069ba0 -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}